Nadolol in thyrotoxicosis

British Journal of Clinical Pharmacology
N R PedenJ Crooks


1 Twenty outpatients with thyrotoxicosis received the non-selective beta-adrenoceptor antagonist nadolol as sole treatment for 3 weeks. 2 Clinical improvement as measured by reduction in thyrotoxicosis therapeutic index occurred during the first week of treatment and was continued thereafter, and was accompanied by a significant reduction in serum T3 and elevation of serum reverse T3. 3 As measured by reduction in exercise heart rate, during chronic dosing nadolol 160 mg once daily produced blockade of beta-adrenoceptors for 12 h in all patients and 24 h in all but 2. 4 Wide interindividual variability was noted in steady state plasma nadolol concentrations, in part related to age and renal function. 5 Steady state plasma nadolol concentrations were related to reduction in heart rate.


Aug 1, 1977·Journal of Pharmaceutical Sciences·E Ivashkiv
Dec 1, 1978·Clinical Pharmacology and Therapeutics·R LindsayG H Beastall
Sep 1, 1978·British Journal of Clinical Pharmacology·D G McDevitt, J K Nelson
Dec 1, 1979·British Journal of Clinical Pharmacology·L E MurchisonP D Bewsher
May 1, 1979·Clinical Endocrinology·J FeelyJ Crooks
May 1, 1977·The Journal of Clinical Endocrinology and Metabolism·R P VerhoevenM A Schalekamp
Jul 1, 1978·Clinical Endocrinology·J SaundersP H Sönksen
Feb 15, 1979·The New England Journal of Medicine·S RubenfeldP O Kohler
Oct 1, 1975·British Journal of Clinical Pharmacology·J K Nelson, D G McDevitt
Apr 1, 1976·British Journal of Clinical Pharmacology·L E MurchisonW R Ferrier
May 3, 1976·Clinica Chimica Acta; International Journal of Clinical Chemistry·J SethW J Irvine
May 29, 1971·Lancet·K Siersbaek-NielsenM Kristensen
May 17, 1969·Lancet·R G ShanksD A Montgomery
Jan 1, 1980·Clinical Pharmacology and Therapeutics·K L DuchinD A Willard
Sep 17, 1981·The New England Journal of Medicine·W H Frishman
Dec 1, 1981·British Journal of Clinical Pharmacology·G R JonesD Wynford-Thomas
Jan 1, 1982·European Journal of Clinical Pharmacology·A AroH Sundquist
Apr 1, 1981·Annals of Internal Medicine·J FeelyJ Crooks
Sep 1, 1980·Clinical Endocrinology·J HowP D Bewsher
Dec 1, 1981·Acta Endocrinologica·J Feely
Jul 1, 1980·Clinical Pharmacology and Therapeutics·J FeelyJ Crooks
Oct 1, 1980·European Journal of Clinical Pharmacology·O R NilssonL Tegler
Apr 1, 1974·British Journal of Clinical Pharmacology·S G CarruthersR G Shanks

❮ Previous
Next ❯


Jun 14, 1984·The New England Journal of Medicine·R D Utiger
Jun 16, 1994·The New England Journal of Medicine·J A Franklyn
Jan 1, 1991·Thyroid : Official Journal of the American Thyroid Association·W M Wiersinga
Jul 1, 1992·The American Journal of Medicine·D L Geffner, J M Hershman
Apr 1, 1984·Anaesthesia·W F HamiltonJ Feely
Nov 1, 1982·The British Journal of Surgery·N R PedenT E Isles
Feb 24, 2018·BMC Research Notes·Aurel T TankeuEugene Sobngwi
May 1, 1992·Postgraduate Medical Journal·D CameronM Turner
May 1, 1992·Postgraduate Medical Journal·M Mercer
Jan 1, 1987·Acta Medica Scandinavica·L KayserJ E Mølholm Hansen

❮ Previous
Next ❯

Related Concepts

Related Feeds

Adrenergic Receptors: Trafficking

Adrenergic receptor trafficking is an active physiological process where adrenergic receptors are relocated from one region of the cell to another or from one type of cell to another. Discover the latest research on adrenergic receptor trafficking here.